Mavacamten Approved in Canada Published on November 11, 2022 by hcmbeat Bristol Myers Squibb’s first in class drug mavacamten (brand name Camzyos) has been approved by Health Canada for the treatment of obstructive hypertrophic cardiomyopathy. Share this: Share on Facebook (Opens in new window) Facebook Share on X (Opens in new window) X Email a link to a friend (Opens in new window) Email Share on LinkedIn (Opens in new window) LinkedIn Share on Pinterest (Opens in new window) Pinterest More Print (Opens in new window) Print Like Loading...
HCM Beat 